Bio-Rad Laboratories has achieved a significant regulatory milestone with EU Quality Management Systems certification under the In Vitro Diagnostic Regulation (IVDR), enabling CE marking for 40 infectious disease molecular quality control products from their Exact Diagnostics brand.
FairJourney Biologics S.A., a global leader in antibody discovery and development based in Porto, Portugal, has announced the formation of a new Supervisory Board aimed at enhancing the company’s strategic positioning and accelerating innovation in antibody research. The board, comprising distinguished industry veterans with extensive expertise in biopharmaceutical development, will focus on defining key growth […]
The equity-free accelerator programme, based in Basel’s life sciences hub, aims to address the 80% failure rate of healthtech startups by providing direct access to pharmaceutical expertise and resources.
Cancer diagnostics in Germany is set to enter a new phase as Labor Dr. Wisplinghoff collaborates with US-based Genomic Testing Cooperative to implement advanced molecular testing capabilities, with RNA analysis at the forefront of this precision medicine initiative.
German biotechnology company Navigo Proteins has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to accelerate development of targeted radiotheranostics. The partnership aims to combine Navigo’s expertise in precision carrier molecules with SCK CEN’s capabilities in radioisotope production and preclinical testing.
Wiley has announced the release of its 2025 edition of the Mass Spectra of Designer Drugs database, a critical resource expanding forensic laboratories’ capabilities in the identification of illicit substances. The updated database represents a substantial advancement in analytical tools available to forensic scientists combating the proliferation of novel psychoactive substances.
New research reveals over 3 million children died globally from AMR-related infections in 2022, with particular concerns about increasing use of critical antibiotic classes.
New research identifies interleukin-6 as a superior diagnostic biomarker for sepsis in high-risk populations including neonates, children, and pregnant women.
Safety concerns prompt Pfizer to terminate development of once-daily oral GLP-1 receptor agonist for weight management, despite promising pharmacokinetic data from recent dose-optimisation studies.
Basel’s equity-free pharma-focused accelerator programme returns to bridge the gap between healthtech innovations and pharmaceutical R&D needs.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.